Evidence map›Paper›PMID 30176543›Full record

Trial reportCancer epidemiology2018

EPHA2 sequence variants are associated with susceptibility to Kaposi's sarcoma-associated herpesvirus infection and Kaposi's sarcoma prevalence in HIV-infected patients.

Melissa J Blumenthal, Charlotte Schutz, Graeme Meintjes, Zainab Mohamed, Marc Mendelson, Jon M Ambler, Denise Whitby, Romel D Mackelprang, Sinead Carse, Arieh A Katz and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer epidemiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Melissa J BlumenthalDivision of Medical Biochemistry and Structural Biology, Department of Integrative Biomedical Sciences, University of Cape Town, South Africa; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
Charlotte SchutzInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, South Africa.
Graeme MeintjesInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa; Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, South Africa.
Zainab MohamedDivision of Radiation Oncology, Department of Radiation Medicine, University of Cape Town, South Africa.
Marc MendelsonDivision of Infectious Diseases & HIV Medicine, Department of Medicine, University of Cape Town, South Africa.
Jon M AmblerComputational Biology Group, Department of Integrative Biomedical Sciences, University of Cape Town, South Africa.
Denise WhitbyViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, NIH, USA.
Romel D MackelprangUniversity of Washington, USA.
Sinead CarseDivision of Medical Biochemistry and Structural Biology, Department of Integrative Biomedical Sciences, University of Cape Town, South Africa; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
Arieh A KatzDivision of Medical Biochemistry and Structural Biology, Department of Integrative Biomedical Sciences, University of Cape Town, South Africa; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
Georgia SchäferDivision of Medical Biochemistry and Structural Biology, Department of Integrative Biomedical Sciences, University of Cape Town, South Africa; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa. Electronic address: georgia.schafer@uct.ac.za.
University of Cape Town · ZALeidos (United States) · USUniversity of Washington · US

Funding

NCI NIH HHS HHSN261200800001EWellcome TrustWellcome Trust 098316
6 · The paper itself

Abstract

backgroundTo determine if variations exist in the KSHV host receptor EPHA2's coding region that affect KSHV infectivity and/or KS prevalence among South African HIV-infected patients.

methodsA retrospective candidate gene association study was performed on 150 patients which were randomly selected from a total of 756 HIV-infected patients and grouped according to their KS status and KSHV serodiagnosis; namely group 1: KS

results100% (95% CI 92.9-100%) of the KS positive patients, and 31.6% (95% CI 28.3-35.1%) of the KS negative patients were found to be KSHV seropositive. Aggregate variation across the entire EPHA2 coding region identified an association with KS (OR = 6.6 (95% CI 2.8, 15.9), p = 2.2 × 10

conclusionsVariations in the KSHV entry receptor gene EPHA2 affected susceptibility to KSHV infection and KS development in a South African HIV-infected patient cohort.

Indexed as

Genetic VariationAdultEphrin-A2FemaleHerpesvirus 8, HumanHIVHIV InfectionsHumansMaleMiddle AgedPrevalencePrognosisReceptor, EphA2Retrospective StudiesSarcoma, KaposiSouth AfricaEPHA2 protein, humanEphrin-A2Receptor, EphA2EpidemiologyHIVKaposi’s sarcomaKaposi’s sarcoma-associated herpesvirusReceptor EPHA2South Africa

Identifiers

PMID30176543
PMCPMC6206435
OpenAlexW2889437683

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.